CLTR COULTER PHARMACEUTICAL Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Pseudo Biologist who wrote (353)	11/16/1999 11:49:00 PM
From: Vector1	Read Replies (2) of 666

PB, Don't loose faith. Lets take a hard look at the Fludara/Bex and the Zevalin abstracts at ASH before settling at 20. I agree that managements inability to get the BLA filed is inexcuseable. I do not know whether it was Tidmarsh's fault but he and Bingham are ultimately responsible. The company and SKB have consistently said that additonal trials were not being requested. I believe they were not lying. However given that the filing date now appears to be pushed to the end of Q1 I wonder if the FDA requested final hot v. cold data. I just do not know how else to explain this. V1

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next